Open Access<p>Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD</p>
Author(s) -
Arava Leela Mohana Reddy,
Sowmya P. Lakshmi,
Asoka Banno,
Raju C. Reddy
Publication year - 2020
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s230188
Subject(s) - roflumilast , dexamethasone , glucocorticoid receptor , copd , glucocorticoid , medicine , sensitivity (control systems) , receptor , pharmacology , endocrinology , chemistry , electronic engineering , engineering
Glucocorticoids are commonly prescribed to treat inflammation of the respiratory system; however, they are mostly ineffective for controlling chronic obstructive pulmonary disease (COPD)-associated inflammation. This study aimed to elucidate the molecular mechanisms responsible for such glucocorticoid inefficacy in COPD, which may be instrumental to providing better patient outcomes. Roflumilast is a selective phosphodiesterase-4 (PDE4) inhibitor with anti-inflammatory properties in severe COPD patients who have a history of exacerbations. Roflumilast has a suggested ability to mitigate glucocorticoid resistance, but the mechanism is unknown.